

LFW



MAIL STOP - PCT
Attorney Docket No.: 27500U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BARSIG, et al.

Art Unit: Unknown

Examiner: Unknown

Appl. No.: 10/586,121

Appl. Filing Date: July 14, 2006

Intl. Appl. No.: PCT/EP2005/050206

Intl. Filing Date: January 19, 2005

Title: **N-4-(6-(HETERO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS**

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:


- 1) Submission of Documents to Complete Filing Requirements;
- 2) PCT/IB/373 (International Preliminary Report on Patentability);
- 3) PCT/ISA/237 (Written Opinion of the International Searching Authority);
- 4) Information Disclosure Statement;
- 5) PTO Form-1449 with 11 cited references, and copies of 10 of the 11 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

September 29, 2006

By:


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le

MAIL STOP - PCT
Attorney Docket No.: 27500U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BARSIG, et al.

Art Unit: Unknown

Examiner: Unknown

Appl. No.: 10/586,121

Appl. Filing Date: July 14, 2006

Intl. Appl. No.: PCT/EP2005/050206

Intl. Filing Date: January 19, 2005

Title: **N-4-(6-(HETERO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS**

SUBMISSION OF DOCUMENTS
TO SUPPLEMENT FILING DOCUMENTS UNDER 35 USC 371

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In order to supplement the filing documents for the National Phase filing under USC 371 commenced on **JULY 14, 2006**, applicant now submits the following documents:

- 1) PCT/IB/373 (International Preliminary Report on Patentability);
- 2) PCT/ISA/237 (Written Opinion of the International Searching Authority);
- 3) Information Disclosure Statement;
- 4) PTO Form-1449 with 11 cited references, and copies of 10 of the 11 cited references.

Please charge any deficiency or credit any overpayment to our Deposit Account Number 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

September 29, 2006

By: 

Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BARSIG, et al.

Appl. No.: 10/586,121

Appl. Filing Date: July 14, 2006

Intl. Appl. No.: PCT/EP2005/050206

Intl. Filing Date: January 19, 2005

Title: **N-4-(6-(HETERO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. [] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. [] The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113,

or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

[] Certification report(e) below; and

[] a check in the amount as required by 1.17(p).

d. [] The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XXX] Copies of the documents are attached herewith with a completed PTO Form-1449.

or

[] Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

[XXX] and / or
Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

September 29, 2006 By: 

~~Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375~~

Le

PTO FORM-1449 INFORMATION DISCLOSURE CITATION		In re Application of: BARSIG, et al.		
		Application No: 10/586,121	Art Unit: Unknown	
		Filed: July 14, 2006	Examiner: Unknown	
		U.S. PATENT DOCUMENTS		
Examiner Initial	Document Number	Issue / Publication Date	Inventor	Filed
	5,821,246 (corresponds to WO96/15118)	10/13/1998	Brown et al.	11/8/1995
A1				
A2				
A3				
A4				
A5				
FOREIGN PATENT DOCUMENTS				
Examiner Initial	Document Number	Publication Date	Country	Translation
A6	02/12198 A2	2/14/2002	WO	N/A
A7	01/47897 A1	7/5/2001	WO	N/A
A8	02/094831 A1	11/28/2002	WO	N/A
A9	2005/026129 A1	3/24/2005	WO	N/A
A10	2004/048365 A1	6/10/2004	WO	N/A
A11	99/24440 A1	5/20/1999	WO	N/A
A12	99/06378 A1	2/11/1999	WO	N/A
A13	03/037891 A1	5/8/2003	WO	N/A
A14	2006/000589 A1	1/5/2006	WO	N/A
A15				
OTHER				
Examiner Initial	(Including Author, Title, Date, Pertinent Pages, etc.)			
A16	Reuveni, H., et al., "Toward a PKB Inhibitor: Modification of a Selective PKA Inhibitor by Rational Design", <u>Biochemistry</u> , Vol. 41, pages 10304-10314, (2002).			
A17				
A18				
A19				
A20				
Examiner		Date Considered		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				